Evaluation Study of RDTs Detecting Antibodies Against HCV

CompletedOBSERVATIONAL
Enrollment

1,710

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

March 15, 2019

Study Completion Date

March 15, 2019

Conditions
Hepatitis C
Interventions
DIAGNOSTIC_TEST

13 Rapid Diagnostic Tests and reference tests

"Rapid diagnostic tests:~1. HCV antibody test (under development); bioLytical Laboratories~2. DPP® HCV (under development); Chembio Diagnostic Systems~3. HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~4. Rapid Anti-HCV Test; InTec~5. First Response HCV Card Test; Premire Medical Corporation~6. Signal HCV Ver 3.0; Arkray healthcare~7. TRI DOT HCV; J. Mitra \& Co~8. Triplex HIV, HCV, HBsAg; Biosynex SA~9. Standard Q HCV Ab; SD Biosensor~10. HCV Hepatitis Virus Antibody Test; Artron Laboratories~11. SD Bioline HCV; Abbott Diagnostics~12. OraQuick HCV; OraSure~13. Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"

Trial Locations (3)

2000

Institute of Tropical Medicine, Antwerp

0198

National Center for Disease Control & Public Health/Lugar Center, Tbilisi

Unknown

Nigerian Institute of Medical Research, Lagos

All Listed Sponsors
collaborator

Institute of Tropical Medicine, Belgium

OTHER

collaborator

Nigerian Institute of Medical Research

OTHER_GOV

collaborator

Richard Lugar Centre for Public Health Research, Georgia

UNKNOWN

lead

Foundation for Innovative New Diagnostics, Switzerland

OTHER